Binamo Genomics Inc. (NASDAQ: BNGO) gained 3.17% after the company appointed Richard Shippy as its Chief Business Officer. Shippy was among Affymetrix’s transformational leaders who delivered microarrays into the clinical and cleared the path for the first-ever FDA-approved application of microarrays in cytogenetics with the CytoScan HD Array from Affymetrix.
Shippy appointed Bionano chief business officer.
At Bionano, Shippy will be in charge of product strategy, expand its business into new markets, and strategically expand its product and technology portfolios. Bionano Genomics CEO Erik Holmlin said that Shippy is an excellent addition. The company puts critical elements to accelerate widespread global adoption of optical genome mapping through the Saphryr® system.
Shippy understands the clinical and biological importance of structural variations (SVs) and has dedicated his career to creating the most acceptable technology for identifying SVs for various applications. Holman said they believe his experience at Affymetrix and Illumina has provided him with the necessary background to assist Bionano in transforming the cytogenetics market with OGM. Also, his experience as a co-founder of Cradle genomics has afforded him the entrepreneurial experience and the necessary patient and physician perspective to recognize that what the company does with OGM matters in patients’ lives.
Shippy was delighted to join Bionano
Commenting in the appointment, Shippy said that Bionano had piqued his interest, and he was excited to be a part of it. He said he is grateful to Erik and the Bionano board for providing him with the once-in-a-lifetime chance. He added that he felt that genome structure and SVs are considerably more critical biology and pathology drivers than single-nucleotide variants throughout his career. The SVs discovery tech has hampered the capacity to harness and utilize them in research and therapy.